Janssen Biotech files lawsuits for infringement of cell culture media patent

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Sign up
eng / esp

Janssen Biotech files lawsuits for infringement of cell culture media patent

Biosimilars/News | Posted 26/08/2016 0 Post your comment

In ongoing litigation over infliximab biosimilars, Janssen Biotech, manufacturer of Remicade (infliximab), has filed two new lawsuits against Celltrion Healthcare, Hospira and HyClone Laboratories, a subsidiary of GE Healthcare Life Sciences, over the use of cell cultures grown for use in Celltrion’s biosimilar Remsima (infliximab), and Hospira’s biosimilar Inflectra (infliximab).

Janssen Biotech claims that HyClone Laboratories infringed their 083 patent for large-scale manufacture of Cellitron’s Remsima outside the US and plans to use the media for the manufacture of Remsima within the US. They believed that the infringement dates back to as early as 2010.

The lawsuit states that ‘Celltrion controlled the development of the infringing media, directing details of its composition and instructing HyClone to use the combinations of ingredients that together infringe the claims of the 083 patent’.

In March 2015, Janssen Biotech, along with New York University, sued Celltrion and Hospira claiming technical infringement by not providing required manufacturer information in violation of the Biologics Price Competition and Innovation Act.

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Source: BioPharm, Justia